Next Article in Journal
Canadian Melanoma Conference Recommendations on High-Risk Melanoma Surveillance: A Report from the 14th Annual Canadian Melanoma Conference; Banff, Alberta; 20–22 February 2020
Previous Article in Journal
Results from a Theory-Guided Survey to Support Breast Cancer Trial Participation: Barriers, Enablers, and What to Do about them
Article

Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study

1
Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC J1H 5H3, Canada
2
Hôpital Universitaire du Sacré-Cœur de Montréal, Montreal, QC H4J 1C5, Canada
3
Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada
4
Centre de Recherche du CHUS (CRCHUS), Sherbrooke, QC J1H 5N4, Canada
*
Author to whom correspondence should be addressed.
Membres of Groupe des Maladies Plasmocytaires du Québec.
Curr. Oncol. 2021, 28(3), 2029-2039; https://doi.org/10.3390/curroncol28030188
Received: 25 March 2021 / Revised: 20 April 2021 / Accepted: 21 May 2021 / Published: 26 May 2021
(This article belongs to the Section Hematology)
Background—smoldering multiple myeloma (SMM) risk of progression to multiple myeloma (MM) is highly heterogeneous and several models have been suggested to predict this risk. Lakshman et al. recently proposed a model based on three biomarkers: bone marrow plasma cell (BMPC) percentage > 20%, free light chain ratio (FLCr) > 20 and serum M protein > 20 g/L. The goal of our study was to test this “20/20/20” model in our population and to determine if similar results could be obtained in another cohort of SMM patients. Method—we conducted a retrospective, single center study with 89 patients diagnosed with SMM between January 2008 and December 2019. Results—all three tested biomarkers were associated with an increased risk of progression: BMPC percentage ≥ 20% (hazard ratio [HR]: 4.28 [95%C.I., 1.90–9.61]; p < 0.001), serum M protein ≥ 20 g/L (HR: 4.20 [95%C.I., 1.90–15.53]; p = 0.032) and FLCr ≥ 20 (HR: 3.25 [95%C.I., 1.09–9.71]; p = 0.035). The estimated median time to progression (TTP) was not reached for the low and intermediate risk groups and was 29.1 months (95%C.I., 3.9–54.4) in the high-risk group (p = 0.006). Conclusions—the 20/20/20 risk stratification model adequately predicted progression in our population and is easy to use in various clinical settings. View Full-Text
Keywords: smoldering multiple myeloma; multiple myeloma; risk stratification model smoldering multiple myeloma; multiple myeloma; risk stratification model
Show Figures

Figure 1

MDPI and ACS Style

Tessier, C.; Allard, T.; Boudreault, J.-S.; Kaedbey, R.; Éthier, V.; Fortin, F.; Pavic, M. Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study. Curr. Oncol. 2021, 28, 2029-2039. https://doi.org/10.3390/curroncol28030188

AMA Style

Tessier C, Allard T, Boudreault J-S, Kaedbey R, Éthier V, Fortin F, Pavic M. Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study. Current Oncology. 2021; 28(3):2029-2039. https://doi.org/10.3390/curroncol28030188

Chicago/Turabian Style

Tessier, Camille; Allard, Thomas; Boudreault, Jean-Samuel; Kaedbey, Rayan; Éthier, Vincent; Fortin, Fléchère; Pavic, Michel. 2021. "Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study" Curr. Oncol. 28, no. 3: 2029-2039. https://doi.org/10.3390/curroncol28030188

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop